SKINThe Beauty Health Company shows mixed signals. Fundamentally, it has a strong market position in the aesthetics industry, but profitability and growth have been inconsistent. Technically, the stock is trading below key moving averages, indicating short-term weakness.
The Beauty Health Company operates in the growing global beauty and wellness market. Increasing consumer interest in non-invasive aesthetic treatments and self-care provides a positive backdrop, though competition is also rising.
While the company holds a strong brand in HydraFacial, its recent financial performance shows revenue decline and net losses. Debt levels are significant relative to current cash, and the company has not paid dividends.
The stock is trading below key longer-term moving averages, indicating a bearish trend. While some short-term indicators suggest potential for a bounce, the overall trend is not yet bullish.
| Factor | Score |
|---|---|
| Aesthetic Treatments Market Growth | 85 |
| Consumer Spending on Beauty & Wellness | 75 |
| Competitive Landscape | 50 |
| Innovation & Technology Adoption | 70 |
| Geographic Expansion | 70 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 25 |
| Balance Sheet Health | 30 |
| Cash Flow | 65 |
| Earnings Surprise | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 65 |
| Short-Term Oscillators | 60 |
Strong Cash Position
The company has a substantial cash and cash equivalents of $370.06M (Q4 2024), providing financial flexibility and stability.
Positive Free Cash Flow
The company generated positive free cash flow of $9.34M in the latest annual period (FY 2024), indicating its ability to cover operational and capital expenditures.
Negative Net Income and Margins
The company reported a net loss of -$29.1M in 2024 with a net margin of -8.7%, and a net loss of -$100.1M in 2023 with a net margin of -25.2%, indicating current unprofitability.
Negative P/E Ratio
The Price-to-Earnings (PE) ratio is negative (-5.8 TTM, -6.9 for 2024), which is not uncommon for companies experiencing losses but signals a lack of current earnings profitability.
August 2025
8
Next Earnings Date
H: $-0.02
A: $-0.02
L: $-0.02
H: 76.70M
A: 74.67M
L: 72.80M
The Beauty Health Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells esthetic technologies and products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers. The Beauty Health Company was founded in 1997 and is headquartered in Long Beach, California.
1.66 USD
The 39 analysts offering 1 year price forecasts for SKIN have a max estimate of 2.00 and a min estimate of 1.30.